article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer.

article thumbnail

Six Biosimilars Part of EMA’s Authorization Recommendations in June

PharmTech

Zemcelpro is used to treat patients that require allogeneic hematopoietic stem cell transplantation following chemotherapy or radiotherapy when no other type of suitable donor cells is available. Two generic drugs were also approved.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to help patients avoid food poisoning

The Checkup by Singlecare

Choose piping-hot, freshly cooked meals when available; otherwise, choose pre-packaged foods. Immunocompromised individuals may include people with diabetes, kidney or liver disease, autoimmune conditions, HIV, or those undergoing chemotherapy or radiation. Skip street vendor food in areas that may have limited food safety oversight.

article thumbnail

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

Experts praise the reforms to rare disease and antimicrobial research, but they worry that some provisions in the EU Pharma Package may harm innovation on the continent, contrary to its stated objectives. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi.

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. How will RFK Jr’s American dream for vaccines play out?

article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

In June 2025, the European Commission authorised Takeda’s Adcetris (brentuximab vedotin), an antibody-drug conjugate, combined with chemotherapy for treating adults who are newly diagnosed with Stage IIb Hodgkin’s lymphoma with risk factors or at Stage III/IV. Sign up for our daily news round-up!

FDA
article thumbnail

Biocon’s Denosumab biosimilars gain EU marketing authorisation

Pharmaceutical Technology

Go deeper with GlobalData Reports LOA and PTSR Model - Denosumab Biosimilar in Bone Metastasis Reports LOA and PTSR Model - Denosumab Biosimilar in Chemotherapy Effects Data Insights The gold standard of business intelligence. How will RFK Jr’s American dream for vaccines play out? Find out more Sign up for our daily news round-up!